The Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Coronary Artery Disease
Overview
Authors
Affiliations
Platelet membrane glycoprotein IIb/IIIa inhibitors, a new class of potent antiplatelet agents, have been used in the treatment of acute coronary syndromes as well as in the prevention of complications after percutaneous coronary interventions. Approximately 50,000 patients with coronary artery disease have been enrolled in randomized studies of glycoprotein IIb/IIIa inhibitors. The purpose of this article is to review the pharmacology of glycoprotein IIb/IIIa inhibitors, the results of the clinical trials using these agents, and their current use in percutaneous coronary interventions and the treatment of acute coronary syndromes.
Apixaban for massive intracoronary thrombosis: A case series.
Esenboga K, Sahin E, Ozyuncu N, Tan T, Atmaca Y Anatol J Cardiol. 2021; 25(9):661-664.
PMID: 34498598 PMC: 8443197. DOI: 10.5152/AnatolJCardiol.2021.32746.
Kwon H Prev Nutr Food Sci. 2019; 24(1):56-63.
PMID: 31008097 PMC: 6456239. DOI: 10.3746/pnf.2019.24.1.56.
Sukul D, Seth M, Schreiber T, Hanzel G, Khandelwal A, Cannon L J Interv Cardiol. 2017; 30(4):291-300.
PMID: 28543770 PMC: 6850214. DOI: 10.1111/joic.12388.
Shin J, Kwon H, Cho H, Rhee M, Park H J Ginseng Res. 2016; 40(4):359-365.
PMID: 27746688 PMC: 5052406. DOI: 10.1016/j.jgr.2015.11.003.
Kwon H, Shin J, Cho H, Rhee M, Park H J Ginseng Res. 2016; 40(1):76-85.
PMID: 26843825 PMC: 4703804. DOI: 10.1016/j.jgr.2015.05.004.